Increased intestinal permeability has been identified as a factor in a wide range of conditions many of which, on the surface, appear to have nothing to do with the gut: IBS IBD: Ulcerative colitis & Crohn's disease Coeliac disease Type 1 and 2 diabetes Hashimotos thyroiditis Rheumatoid arthritis Alopecia Multiple sclerosis Parkinsons disease Polycystic Ovarian Syndrome (PCOS) Alcoholic liver disease Liver cirrhosis Acute pancreatitis Chronic heart failure Depression (2-5) Chronic Fatigue Syndrome / M.E Psoriasis Acne Long COVID Among many others
- Some formularies might include only one of the two highly potent GLP-1 medications, which is reasonable as both offer substantial benefit
Browse our directory of verified peptide therapy clinics to find a licensed provider.
Simultaneously, NO, produced by LA, is employed to deplete GSH and generate RNS, forming an RS storm to eradicate the biofilm
Progressive decrease of melatonin production over consecutive days of simulated night work
For a deeper look at the role of appetite control in weekly GLP-1 treatment, see our guide on what to do after missing a weekly GLP-1 injection